Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.

AP1189
An Oral Selective Melanocortin Agonist
Our lead drug candidate AP1189 is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. AP1189 is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
BioStock regarding TXP – December 20, 2022
BioStock – November 4, 2022
-
March 30, 2023 Non RegulatorySynAct Pharma introduces resomelagon as generic name for AP1189
-
March 28, 2023 Non RegulatorySynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023
-
February 17, 2023 RegulatorySynAct Pharma publishes Annual Results for 2022
-
November 4, 2022 RegulatorySynAct Pharma publishes Q3 2022 interim report
-
March 2023Company presentation
-
December 20, 2022BioStock: Interview regarding TXP

A MESSAGE FROM OUR CEO